A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy
PHASE2
First line chemotherapy treatment regimens for metastatic colorectal cancer...
Status
Unknown
Location
Associació Catalana per la Recerca Oncològica i les Seves Implicacions Sanitaries i Socials
Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques
PHASE2
Open label Phase II study of FOLFIRI + Panitumumab using ultra-selection te...
Status
Completed
Location
Spanish Cooperative Group for Digestive Tumour Therapy
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
PHASE3
This phase III trial compares hepatic arterial infusion (HAI) (pump chemoth...
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
PHASE3
The aim of this study is to compare progression free survival (PFS) in trea...